Lisa Cook sues Trump over firing attempt, emergency hearing set
Lisa Lynn Decker, Chief Business Officer of IGM Biosciences (NASDAQ:IGMS), sold 4,409 shares of common stock on July 23, 2025, for a total of $5611. The transaction comes as IGM Biosciences, currently valued at $76.4 million, has seen its stock decline nearly 89% over the past year. According to InvestingPro analysis, the company appears undervalued at current levels.
The shares were sold at a weighted average price of $1.2728, with individual sales prices ranging from $1.27 to $1.275. The sale was executed to cover tax withholding obligations related to the vesting of restricted stock units. Following the transaction, Decker directly owns 68,169 shares of IGM Biosciences. InvestingPro data reveals the company holds more cash than debt on its balance sheet, though it’s quickly burning through available funds. Discover 8 more exclusive ProTips and comprehensive insider trading analysis with an InvestingPro subscription.
In other recent news, IGM Biosciences has announced a definitive merger agreement with Concentra Biosciences. Under the terms of the deal, Concentra will acquire IGM Biosciences for $1.247 in cash per share, along with a non-tradeable contingent value right (CVR). This CVR entitles shareholders to 100% of IGM’s closing net cash exceeding $82 million and 80% of any net proceeds from the sale of certain product candidates and intellectual property within a year of the transaction’s closing. In another development, IGM Biosciences has ended its collaboration and license agreement with Genzyme Corporation, a Sanofi (NASDAQ:SNY) entity. This agreement, originally established in March 2022, was focused on developing IgM antibodies for diseases like cancer and immunological disorders. The termination notice was received by IGM Biosciences on May 5, 2025, and will be effective 30 days from that date. Both IGM Biosciences and Genzyme Corporation have agreed that continuing their collaboration is not in their best interests.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.